Oncorena is pleased to announce that the FDA has approved the Company's IND application to initiate the Phase I/II study Oncorella-1: A Phase 1/2, open label, single arm study on safety, tolerability ...

Orellanine is highly specific to the kidney and induces irreversible renal failure. It is clinically well-known that orellanine does not affect organs other than the kidneys. In pioneering ...

Oncorena, a Swedish pharma company, announced that the US FDA has approved the company’s IND application to initiate the phase I/II study Oncorella-1: A phase 1/2, open label, single arm study on ...

Renal cell carcinoma (RCC ... in the proximal convoluted tubule of the kidney. The three most common forms of RCC are clear cell RCC, papillary RCC and chromophobe RCC. Angioscore is a ...

To be eligible for enrollment, patients must have histologically confirmed advanced clear cell or papillary RCC ... curative treatment of metastatic renal cell carcinoma in patients with no remaining ...

Dr. Frankie Jackson-Spence presented the final overall survival and new ctDNA analysis from CALYPSO in MET-driven advanced papillary renal cancer. Metastatic papillary renal cancer has poor outcomes, ...

A new study led by Dr. Hilla Chen from the Koret School of Veterinary Medicine at Hebrew University, recently published in ...

This is the third indication for Fabhalta after Novartis won FDA approval of the small molecule in paroxysmal nocturnal hemoglobinuria and primary immunoglobulin A nephropathy.

The approval of iptacopan in reducing proteinuria in adult patients with native kidney C3G was based on data from the randomized, double-blind, placebo-controlled, phase 3 APPEAR-C3G trial.

The FDA approved iptacopan (Fabhalta) as the first treatment to reduce proteinuria in adults with complement 3 glomerulopathy ...